- Home
- EAF vs CDXS Comparison
EAF vs CDXS Comparison
Compare EAF & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EAF | CDXS |
|---|---|---|
| Founded | 1886 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Major Chemicals |
| Sector | Energy | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.9M | 256.3M |
| IPO Year | 2018 | 2008 |
Fundamental Metrics
Financial Performance| Metric | EAF | CDXS |
|---|---|---|
| Price | $9.29 | $2.64 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $11.75 | N/A |
| AVG Volume (30 Days) | 254.0K | ★ 1.4M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $504,134,000.00 | $138,590,000.00 |
| Revenue This Year | $4.25 | $7.73 |
| Revenue Next Year | $12.49 | $14.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $0.70 | $0.96 |
| 52 Week High | $20.32 | $3.87 |
Technical Indicators
Market Signals| Indicator | EAF | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 61.03 | 59.74 |
| Support Level | $7.65 | $2.37 |
| Resistance Level | $9.78 | $2.67 |
| Average True Range (ATR) | 0.78 | 0.20 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 76.88 | 50.48 |
Price Performance
Historical ComparisonAbout EAF GrafTech International Ltd.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products used as raw material in the production of graphite electrodes.
About CDXS Codexis Inc.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.